• New and underused vaccines support

in page functions
  • Since November 2013, Gavi offers support for inactivated poliovirus vaccine and Japanese encephalitis vaccine

  • Yellow fever vaccine support

    Togo Yellow Fever WHO

    Gavi provides yellow fever support for routine immunisation, campaigns in high-risk countries and emergency stockpiles in case of outbreaks.

  • NVS objectives

    • Accelerated introduction of life-saving vaccines
    • Evidence-based decision-making
    • Financial sustainability of immunisation programmes
    • Alignment with national planning and budgetary process

    There is no limit to the number of vaccines that a country can apply for in a single application round, but only one vaccine per country will be funded in a single round and applicants must propose an introduction date within two years of the actual application round.

    Countries can also request support for the partial introduction of a vaccine or a phased rollout. In addition, Gavi funds auto-disable syringes and safety boxes, sent to successful country applicants together with the vaccines.

    Co-financing

    All countries must co-finance Gavi-supported vaccines. The vaccines exempt from co-financing are measles second dose, inactivated polio vaccine (IPV), Japanese Encephalitis, HPV demonstration programmes, and campaigns with measles-rubella, meningococcal A and yellow fever vaccines.

    In no case will Gavi support replace government funds already allocated for the purchase of vaccines.

    Initially, the NVS programme provided five-year support grants with the expectation that countries would cover continued vaccination cost after Gavi’s support ended. Gavi has revised its support timelines to be based on country planning cycles. Today, countries can only request NVS support for the duration of comprehensive Multi-Year Plans for immunisation – this ensures that vaccine rollouts are aligned with the national health and budgetary planning process.

close icon

modal window here